Merck Sharp & Dohme Llc

This study tests a new vaccine called V118C to prevent pneumococcal infections in children. About 210 toddlers and infants will receive the vaccine to check its safety and how well the body responds. The goal is to find a better way to protect young children from this serious bac…

This study tests a new vaccine called V118E, designed to protect against Streptococcus pneumoniae bacteria, which can cause serious infections like pneumonia. Researchers want to see if it is safe and well-tolerated in healthy adults. About 126 participants will receive either th…

This early-stage study is testing two new vaccines (V350A and V350B) designed to prevent diseases caused by the Epstein-Barr virus, such as infectious mononucleosis and certain cancers. About 250 healthy adults and teens will receive either the vaccine or a placebo to check for s…

This large study is testing a new dengue vaccine called V181 in 12,000 healthy children aged 2 to 17. The goal is to see if the vaccine is safe, triggers a good immune response, and reduces cases of dengue fever caused by any of the four dengue virus types. Participants will rece…

This study tests whether the experimental antiviral pill molnupiravir can prevent severe illness from COVID-19 in adults who are at high risk. About 3,000 non-hospitalized volunteers will receive either the drug or a placebo. The main goal is to see if the pill reduces hospitaliz…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard drugs (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that worsened after one prior hormone treatment. The goal is to see i…

This study tests a new drug called MK-1084, given alone or with cetuximab, in people with advanced solid tumors that have a specific gene change (KRAS G12C). The goal is to see if the tumors shrink or disappear and how safe the treatments are. About 150 adults whose cancer has wo…

This study tests an experimental drug called MK-5684 (opevesostat), alone or with other treatments, in people whose prostate cancer has spread and stopped responding to standard hormone therapy. The goal is to find safe doses and see if the drug can shrink tumors or lower PSA lev…

This study tests a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The main goals are to check the drug's safety and see if it can shrink or eliminate tumors. About 180 adults who have already tried other treatments will take p…

This study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia, a condition where the body makes too many platelets. Participants must have tried hydroxyurea without success or had side effects. The goal is to see if…

This study tests a new drug called MK-2870 (sacituzumab tirumotecan) against standard treatments for people with cervical cancer that has returned or spread and has not responded to prior therapy. About 686 participants will be randomly assigned to receive either MK-2870 or a tre…

This study tests adding new experimental drugs to the standard treatment (enfortumab vedotin plus pembrolizumab) for people with advanced bladder cancer that has spread. About 55 participants will receive the combination to see if it is safe and helps shrink tumors. The goal is t…

This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with a specific type of ovarian cancer that has returned after standard chemotherapy. The drug works like a smart bomb, attaching to cancer cells and delivering a toxic payload to destroy them. The trial…

This study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer growing. About 1,123 participants with a specific type of endometrial cancer (pMMR) will receive either the…

This study looks at the long-term safety of the drug sotatercept for people with a specific type of pulmonary hypertension (high blood pressure in the lungs) caused by heart failure. About 130 adults who completed a prior sotatercept study can join. Researchers will monitor side …

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing, compared to the current standard treatment (R-CHOP). About 1,046 partici…

This early-phase study tests a new drug called MK-1084, alone or with other treatments, in people with advanced solid tumors that have a specific KRAS G12C mutation. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 830 participant…

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan, alone or together, in people with advanced small cell lung cancer that stopped responding to prior treatment. About 262 participants will receive these treatments to see if they shrink tumors and are safe…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus standard chemotherapy, o…

This study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, for men with metastatic castration-resistant prostate cancer (mCRPC) that has stopped responding to standard hormone therapy. About 360 participants will join to find safe dose…

This study tests whether adding an experimental vaccine (V940) to the standard immunotherapy drug pembrolizumab after surgery can help prevent lung cancer from returning. It includes 680 adults with stage II to IIIB non-small cell lung cancer whose tumors did not fully disappear …

This study tests a new drug called MK-3120 for people with high-risk bladder cancer that hasn't spread into the muscle. After standard surgery to remove the tumor, participants receive MK-3120 directly into the bladder. The main goals are to check safety and find the right dose. …

This study tests whether adding a targeted drug (MK-1084) to standard immunotherapy after surgery can help prevent KRAS G12C-mutant lung cancer from coming back. About 400 adults with stage IIA-IIIB non-small cell lung cancer who have had complete tumor removal will be randomly a…

This study is testing the safety and how the body handles the antifungal drug posaconazole in infants under 2 years old who have a serious fungal infection. About 40 babies will receive the medicine through an IV or as a liquid to drink. The goal is to find the right dose for thi…

This phase 3 study tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer than pembrolizumab alone. The trial enrolls about 614 adults whose tumors have high PD-L1 levels (50…

This study tests a new medicine called MK-5684 in people with breast, ovarian, or endometrial cancer. The drug works by blocking the body from making certain hormones that can help cancers grow. Researchers want to see if MK-5684 helps people live longer without their cancer gett…

This study tests a new immunotherapy, MK-1045, against a standard treatment (blinatumomab) for people whose B-cell acute lymphoblastic leukemia has returned or not responded to prior therapy. About 340 adults with CD19-positive disease will be randomly assigned to receive either …

This early-stage study tests a new experimental drug, MK-4646, in 28 people with HIV-1 who have never taken HIV medication. The main goals are to see if the drug is safe and tolerable, and to measure how much it lowers the amount of virus in the blood. Participants will take the …

This large study is testing many different drug combinations, including the immunotherapy pembrolizumab and chemotherapy, for people with advanced non-small cell lung cancer. It aims to find which treatments work best for different tumor types. About 1065 adults with stage IV lun…

This study tests whether a new drug (zilovertamab vedotin) combined with standard chemotherapy works better than another approved drug combo for people with a specific type of fast-growing blood cancer called GCB DLBCL. About 594 adults who have not been treated before will recei…

This study tests a new drug, MK-5684, against two standard treatments (abiraterone acetate or enzalutamide) in people with advanced prostate cancer that has spread and no longer responds to hormone therapy or chemotherapy. About 1,310 participants will be randomly assigned to rec…

This study tests a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 adults who have tried all available treatments will take part. The study is curr…

This study tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemotherapy and immunotherapy can help people with advanced squamous non-small cell lung cancer live longer. About 851 adults with stage IV lung cancer will receive pembrolizumab plus chem…

This study tests whether adding belzutifan to fulvestrant works better than standard treatments for people with a common type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. About 120 adults will receive either the new combination or standard…

This study tests a new immunotherapy drug, MK-1045, in about 200 people with two types of non-Hodgkin lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) that have not responded to at least two prior treatments. The main goals are to check safety and see if the cance…

This study tests whether adding new drugs to standard immunotherapy before surgery can completely eliminate cancer cells in people with stage II to IIIB non-small cell lung cancer. About 60 participants will receive the treatment before their tumor is removed, and researchers wil…

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer getting worse. About 770 adults whose cancer responded to second-line chemothera…

This study tests a new drug, patritumab deruxtecan, in children whose liver or muscle cancer has returned or not responded to prior treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to destroy them. The trial aims to check safety, how the drug mo…

This study tests whether adding new drugs, like patritumab deruxtecan, to standard immunotherapy (pembrolizumab) with or without chemotherapy can better control advanced non-small cell lung cancer. About 90 people with untreated stage IV NSCLC will participate. The goal is to see…

This study tests an experimental pill, MK-1084, for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. The goal is to see if the drug can shrink tumors and how safe it is. About 130 participants will receive the drug, and researchers…

This study is for people with advanced nonsquamous non-small cell lung cancer that has spread and no longer responds to standard immunotherapy or chemotherapy. Researchers are testing two antibody drug conjugates (ADCs) — targeted drugs that deliver treatment directly to cancer c…

This study is for people with extensive-stage small cell lung cancer whose disease got worse after first-line treatment including immunotherapy. Researchers are testing new drugs, either alone or combined with pembrolizumab, to see if they can shrink tumors or slow the cancer. Th…

This study tests a new targeted therapy called MK-1084 for people with advanced or spreading non-squamous non-small cell lung cancer that has a specific genetic change (KRAS G12C mutation) and has already been treated before. The main goals are to check the drug's safety and see …

This study tests a medicine called vericiguat in children with heart failure caused by a weak left heart pump. About 342 kids from 1 month to 18 years old will take either vericiguat or a placebo for 16 weeks. The goal is to see if the medicine lowers a heart stress marker (NT-pr…

This study tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab, with or without bevacizumab) as a first maintenance treatment for people with metastatic cervical cancer that has spread. About 1,000 participants will be randomly assigned to the new combo or st…

This study tests a new drug, bomedemstat, against the standard treatment hydroxyurea for people with essential thrombocythemia (ET) who have not yet received treatment to lower their blood cell counts. The goal is to see if bomedemstat is better at safely reducing platelet counts…

This study tests a new medicine called tulisokibart for people with a type of arthritis that causes pain and stiffness in the spine and hips. About 315 adults will receive either the study drug or a placebo to see if it improves symptoms like back pain and morning stiffness. The …

This study tests a drug called I-DXd in people with advanced esophageal cancer that has not responded to previous treatments. I-DXd is designed to attach to cancer cells and deliver a powerful treatment directly to them. The main goal is to see if the drug can shrink or eliminate…

This study is for people with advanced kidney cancer (clear cell type) that came back during or within 2 years after finishing a type of immunotherapy called anti-PD-(L)1. Researchers are testing several new combinations of drugs to see if they are safe and can shrink tumors. Abo…

This study tests two experimental drugs, gocatamig and I-DXd, for people with extensive-stage small cell lung cancer (ES-SCLC) that has spread. The drugs work by helping the immune system attack cancer cells or delivering treatment directly to them. The study will check safety an…

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent lung cancer from coming back after surgery. About 868 people with stage II to IIIB non-small cell lung cancer who have had their tumor completely remov…

This study tests a drug called sotatercept in 42 children aged 1 to 17 who have pulmonary arterial hypertension (PAH), a serious lung condition. The goal is to see if the drug is safe and how the body processes it when added to standard care. This is not a cure, but it may help c…

This study looks at the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in people who have already been taking it in earlier studies. About 3,500 adults with solid tumors or blood cancers can join. The goal is to see how well the drug works over tim…

This study looks at the long-term safety of the drug sotatercept when added to standard treatments for pulmonary arterial hypertension (PAH), a condition where lung blood vessels narrow, making breathing and activity difficult. About 815 adults who completed earlier sotatercept s…

This study tests a new treatment for people with advanced colorectal cancer that has a specific gene change called KRAS G12C. The experimental treatment adds two targeted drugs (calderasib and cetuximab) to standard chemotherapy. The goal is to see if this combination helps peopl…

This study tests new drug combinations, including an antibody-drug conjugate called ifinatamab deruxtecan, with the immunotherapy pembrolizumab (with or without chemotherapy) for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 par…

This study tests a new targeted therapy, sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab after initial chemotherapy for advanced ovarian cancer. About 900 participants will receive either the new treatment or standard care to see if it delays cancer growth. The…

This early-stage study tests a drug called Sacituzumab Tirumotecan (Sac-TMT) given directly into the bladder for people with intermediate-risk non-muscle invasive bladder cancer that has come back. The main goals are to check the drug's safety and find the highest dose people can…

This study is for people with advanced esophageal cancer that has gotten worse after standard treatments like chemotherapy and immunotherapy. Researchers are testing new drug combinations, with or without the immunotherapy drug pembrolizumab, to see if they can shrink tumors or s…

This study looks at the long-term safety of a medicine called tulisokibart for people with moderate to severe Crohn's disease or ulcerative colitis. Participants who already took tulisokibart in an earlier study can join. The main goal is to see if the drug remains safe and toler…

This study tests a drug called pembrolizumab in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, come back, or not responded to treatment. The drug helps the immune system fight cancer. The goal is to see if it can shrink or el…

This study tests whether adding a new medicine called enlicitide decanoate to a standard cholesterol drug (rosuvastatin) lowers bad cholesterol more than a placebo. About 975 adults with high cholesterol will take either the combination or a placebo for 8 weeks. The main goal is …

This study tests a new medicine called ifinatamab deruxtecan (I-DXd) against standard chemotherapy (docetaxel) in people with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The goal is …

This study tests whether adding an experimental drug (V940) to standard BCG immunotherapy can help people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning or spreading. About 308 adults who have not had BCG before will be randomly assig…

This study tests whether a new drug, nemtabrutinib, combined with venetoclax works better than the standard venetoclax plus rituximab for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least one prior t…

This study tests a new drug called MK-2870, alone or with other cancer treatments, in people with advanced colorectal, pancreatic, or bile duct cancers that have spread or can't be removed by surgery. The main goals are to check the drug's safety and see if it can shrink tumors. …

This study tests whether adding a new drug (MK-2870) to standard immunotherapy (pembrolizumab) can better prevent breast cancer from returning in people with triple-negative breast cancer who still had tumor cells after initial chemotherapy and surgery. About 1,530 participants w…

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 adults w…

This study tests whether adding a new targeted drug (zanzalintinib) to standard belzutifan therapy helps people with advanced kidney cancer live longer and keep their cancer from growing. About 758 adults whose cancer worsened after at least one prior treatment will receive eithe…

This study tests whether adding a targeted therapy called Sac-TMT to standard chemotherapy and immunotherapy (pembrolizumab) can eliminate more cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor-low/HER2-negative breast cancer. About 2…

This study tests an experimental oral drug, MK-1026 (nemtabrutinib), in people with certain blood cancers like chronic lymphocytic leukemia, lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the disease. About 490 adults w…

This study tests whether adding new investigational drugs to standard chemotherapy and immunotherapy (pembrolizumab) can safely shrink tumors in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. About 160 adults whose …

This study tests new antibody-drug conjugates (ADCs) for people with advanced squamous lung cancer that stopped responding to standard immunotherapy or chemotherapy. ADCs work like guided missiles, delivering a powerful drug directly to cancer cells. The study will compare these …

This early-stage study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants with cancers like head and…

This early-stage study tests a new medicine called MK-1403 in 52 adults with type 2 diabetes. The main goals are to check if it is safe and well-tolerated, and to measure how the body processes it. Researchers will also look at its effect on a blood marker of inflammation (hsCRP)…

This study tests a drug called belzutifan in people with certain rare or advanced cancers, including pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, and tumors linked to von Hippel-Lindau disease. The goal is to see if the drug shrinks tumors or stops them from …

This study tests an experimental drug called MK-8690 for people with moderate to severe ulcerative colitis, a chronic gut condition causing inflammation and symptoms like diarrhea and bleeding. About 100 adults will receive either the drug or a placebo to see if it can bring abou…

This large Phase 3 study compares a new drug, nemtabrutinib, with two standard treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet received any therapy. The goal is to see if nemtabrutinib works as we…

This study looks at the long-term safety and effectiveness of the drug belzutifan in people with advanced solid tumors or von Hippel-Lindau (VHL) disease. Participants must already be taking belzutifan in another study. The main goal is to see how long people live after starting …

This study tests whether adding the experimental drug MK-1084 to standard immunotherapy (pembrolizumab) helps people with advanced KRAS G12C-mutant non-small cell lung cancer live longer or delay tumor growth. About 600 participants will receive either the combo or pembrolizumab …

This study tests a new HIV-1 treatment (doravirine, alone or combined with other drugs) in children aged 4 weeks to under 12 years who weigh less than 45 kg. The goal is to see how the drug works in the body, check its safety, and ensure it controls the virus. About 84 children w…

This study tests a new medicine called enlicitide decanoate in children and teens with a genetic condition that causes very high cholesterol (HeFH). The goal is to see if the drug safely lowers bad cholesterol more than a placebo. About 153 participants will receive either the dr…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who are already doing well on the drug bomedemstat. It aims to collect long-term safety information and see how well the drug continues to work. About 400 participants will conti…

This study tests a new medicine called tulisokibart for people with rheumatoid arthritis who are already taking methotrexate. The goal is to see if tulisokibart can reduce joint pain and swelling better than a placebo. About 182 adults with active arthritis will receive different…

This study tests a new drug, MK-2870, alone or with another drug (pembrolizumab), against standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has spread or cannot be removed will be randomly assigned to on…

This study compares the immunotherapy drug pembrolizumab with standard chemotherapy in about 100 Chinese patients whose advanced colorectal cancer has a specific genetic feature (MSI-H or dMMR). The goal is to see if pembrolizumab can better delay cancer growth or improve surviva…

This study tests whether a new drug, sacituzumab tirumotecan, given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep the cancer from growing compared to standard chemotherapy. About 1,000 adults whose cancer has spread and …

This study is testing a new drug called patritumab deruxtecan in people with a type of advanced breast cancer (HER2-positive) that has spread or cannot be removed by surgery. The main goals are to see if the drug is safe and if it can shrink or eliminate tumors. About 81 particip…

This study tests a new combination of drugs (calderasib plus pembrolizumab) against standard chemotherapy plus pembrolizumab for people with a specific genetic type of advanced non-small cell lung cancer (KRAS G12C mutation). The goal is to see if the new combo helps people live …

This study tests whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced squamous non-small cell lung cancer live longer and keep their cancer from growing. About 180 participants will receive eithe…

This study tests a new drug called zilovertamab vedotin in children and young adults (up to age 30) whose blood cancers or solid tumors have come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the cancer. About 90 participants…

This early-phase study tests a new drug called MK-4716, alone or combined with other treatments, in people with advanced or metastatic solid tumors that have a KRAS mutation. The main goals are to check the drug's safety and how well people tolerate it. About 250 participants wil…

This study tests whether a once-weekly combination of two drugs (islatravir and ulonivirine) works as well as a standard daily three-drug regimen for adults newly diagnosed with HIV-1. About 570 participants will be randomly assigned to either the weekly or daily treatment. The m…

This study tests the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participants wi…

This study tests whether a personalized cancer vaccine (intismeran) alone or combined with an immunotherapy (pembrolizumab) can prevent non-small cell lung cancer from returning after surgery. About 876 adults with high-risk stage I lung cancer that was fully removed will be rand…

This study tests whether combining the immunotherapy drug pembrolizumab with other treatments can help men with a hard-to-treat form of prostate cancer that has spread and stopped responding to hormone therapy. About 1,200 participants will receive different drug combinations acr…

This early-phase study tests an experimental drug called MK-0472, given alone or with other cancer drugs (pembrolizumab or MK-1084), in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug helps control t…

This study tests an experimental drug called MK-2214 in 340 people with early Alzheimer's disease. The goal is to see if it can slow the buildup of a harmful protein called tau in the brain, which damages brain cells. Participants will receive either the drug or a placebo, and re…

This study tests whether a combination of two drugs (belzutifan and zanzalintinib) works better than the standard drug cabozantinib for people with advanced kidney cancer that came back after previous treatment. About 904 participants will be randomly assigned to one of the two t…

This study tests a new drug called tulisokibart in 1,200 people with moderate-to-severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut better than a placebo. Participants must have tried other treatments without success. The study lasts up to 52 we…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can stop advanced melanoma from growing or spreading. About 160 people with stage III or IV melanoma that cannot be removed by surgery will receive either the vaccine plus…

This study tests a new drug, sacituzumab tirumotecan, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after prior treatments. About 590 participants will be randomly assigned to receive either the new drug or a chemotherapy chosen by th…

This study is for people with stage IV non-small cell lung cancer who have not had any prior treatment. It tests whether adding new experimental drugs to the standard immunotherapy (pembrolizumab) with or without chemotherapy can shrink tumors or control the disease better. About…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can better prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and i…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. About 290 adults will be randomly assigned to receive either the new combina…

This study is for people with advanced bladder cancer that has stopped responding to standard immunotherapy. It tests new drug combinations, with or without the drug pembrolizumab, to see if they can shrink tumors or slow the disease. About 48 adults will take part, and the main …

This study tests whether adding a new drug (patritumab deruxtecan) to standard chemotherapy and immunotherapy before surgery can eliminate more cancer cells in people with high-risk early-stage triple-negative or hormone-receptor-low breast cancer. About 372 participants will be …

This study tests a new once-monthly pill (MK-8527) to see if it works as well as the standard daily pill for preventing HIV-1 infection. About 4,390 HIV-negative adults who are at risk of HIV will take either the monthly pill or a daily pill for up to 18 months. Researchers will …

This study tests a drug called letermovir to prevent cytomegalovirus (CMV) infection in children and teens who have had a kidney transplant and weigh less than 40 kg. About 40 participants will receive the drug to see how it moves through the body and if it is safe. The goal is t…

This study tests a new monthly pill (MK-8527) to see if it works better than a daily pill for preventing HIV in women. About 4,580 HIV-negative women who are sexually active will take either the monthly pill or a daily standard PrEP pill. The goal is to find a simpler, effective …

This study tests whether the sleep medication suvorexant can help people with opioid use disorder who also have trouble sleeping. About 300 adults on stable medication for opioid use disorder will receive either suvorexant or a placebo for 8 weeks. Researchers will measure sleep …

This study tests a new medicine called tulisokibart for people with active psoriatic arthritis, a condition causing joint pain, swelling, and skin plaques. About 140 adults will receive either the study drug or a placebo to see if it improves symptoms like tender joints and disab…

This early-stage study tests a new medicine called MK-1045 in about 21 people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and well-tolerated at different doses. Researchers will also measure how the drug moves through the body. This is a Phas…

This early-stage study is testing a new weight loss medicine called MK-4082, taken as a pill rather than an injection. Researchers want to see if it is safe and how the body handles different doses. The study involves 120 healthy adults with a body mass index (BMI) between 25 and…

This early-stage study looks at how the drug MK-2828 behaves in people with different levels of kidney function, including those with severe kidney failure or on dialysis. About 24 adults will receive one or two doses, and researchers will measure drug levels in the blood over ti…

This study looks at how the body processes a drug called MK-1084 when the liver is not working normally. Researchers will give a single dose to people with liver impairment and to healthy volunteers, then measure drug levels in the blood over time. The goal is to understand if li…

This study looks at how a new drug called ulonivirine affects the way the body processes two common medications: atorvastatin (for cholesterol) and metformin (for diabetes). It involves 12 healthy adults who will take these drugs with and without ulonivirine to compare drug level…

This study looks at how the drug nemtabrutinib is processed in the body of people with moderate liver impairment compared to healthy individuals. About 32 adults will take a single dose of the drug, and researchers will measure drug levels and safety. The goal is to understand if…

This early-stage study checks if a new experimental HIV medicine, MK-4646, changes the levels of standard HIV drugs (BIC/FTC/TAF and dolutegravir) in the blood. It involves 16 healthy adults and focuses on safety and how the body processes these drugs together. The results will h…

This study looks at how a new drug, MK-2828, interacts with two other medicines in healthy adults. In one part, participants take MK-2828 with itraconazole to see if levels change. In another part, they take MK-2828 multiple times before a single dose of midazolam. The goal is to…

This study tests how a new prostate cancer medicine, opevesostat, behaves in the body when taken with or without itraconazole, a common antifungal drug. Fourteen healthy adult men will receive both drugs in a fixed order, and researchers will measure drug levels in their blood. T…

This study enrolls 330 healthy adults to see if two different autoinjectors deliver the same amount of the drug tulisokibart into the body. Researchers will measure drug levels in the blood and watch for any side effects. The goal is to make sure both devices work the same way be…

This early-stage study in 39 healthy adults checks if a new heart failure medicine called MK-2828 affects how the body handles two common drugs: rosuvastatin and furosemide. The goal is to gather safety and interaction data, not to treat any disease. Participants must be in good …